Published in Drug Law Weekly, February 8th, 2005
ImClone Systems reported that the antibodies, IMC-11F8 and IMC-1121B, both of which target growth factor receptors, are being evaluated for their potential as cancer therapeutics. Each antibody was isolated by ImClone Systems using an antibody-fragment (Fab) phage display library licensed to the company by Dyax, and then further optimized by ImClone Systems.
Henry E. Blair, chairman, president and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.